15 research outputs found
Neurons and astrocytes derived from human iPSCs to model Alzheimer´s disease
Alzheimer's disease (AD) is characterized by presenting a complex pathology, not fully resolved yet. This fact, together with the lack of reliable models, has impeded the development of effective therapies. Recently, several studies have shown that functional glial cell defects have a key role in the pathology of AD. However, this glial dysfunction, currently, cannot be correctly modeled using the available animal models, so we hypothesized that cells derived from Alzheimer's patients can serve as a better platform for studying the disease. In this sense, human pluripotent stem cells (hPSC) allow the generation of different types of neural cells, which can be used for disease modeling, identification of new targets and drugs development.
Methods: We have a collection of hiPSCs derived from patients with sporadic forms of AD stratified based on APOE genotype. We have differentiated these cells towards neural cells and mature them to neurons or astrocytes using a serum-free approach, to assess intrinsic differences between those derived from AD patients or healthy controls.
Results: We have implemented a serum-free approach and generated neural precursors and astrocytes from all the lines tested. We observe differences at the phenotypic level and a reduced capacity to differentiate towards neural lineage in those lines derived from APOE4 carriers.
Conclusions: Our preliminary data suggest intrinsic differences in the neural differentiation capacity between cell lines derived from APOE4 or APOE3 carrier subjects. Further experiments would contribute to elucidate novel pathogenic pathways associated with neurodegeneration and susceptible of therapeutic modulation, likely contributing to the development of new effective drugs against AD.This study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, co-financed by FEDER funds from European Union, through grants PI21/00915 (to AG) and PI21/00914 (to JV); by Junta de Andalucia through Consejería de Economía y Conocimiento grants PY18-RT-2233 (to AG) and US-1262734 (to JV) co-financed by Programa Operativo FEDER 2014-2020, Consejeria de Salud grant PI-0276-2018 (to JAGL) and Programa Operativo de Empleo Juvenil SNGJ4-11 to LCP.
Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Glia and neurons from human iPSCs to address the pathology of Alzheimer´s disease
Alzheimer's disease (AD) is characterized by presenting a complex pathology, not fully resolved yet. This
fact, together with the lack of reliable models, has impeded the development of effective therapies.
Recently, several studies have shown that functional glial cell defects have a key role in the pathology of
AD. However, this glial dysfunction, currently, cannot be correctly modeled using the available animal
models, so we hypothesized that cells derived from Alzheimer's patients can serve as a better platform for
studying the disease. In this sense, human pluripotent stem cells (hPSC) allow the generation of different
types of neural cells, which can be used for disease modeling, identification of new targets and drugs
development.
Methods:
We have a collection of hiPSCs derived from patients with sporadic forms of AD stratified based on APOE
genotype. We have differentiated these cells towards neural cells and mature them to neurons or
astrocytes using a serum-free approach, to assess intrinsic differences between those derived from AD
patients or healthy controls.
Results:
We have implemented a serum-free approach and generated neural precursors and astrocytes from all the
lines tested. We observe differences at the phenotypic level and a reduced capacity to differentiate
towards neural lineage in those lines derived from APOE4 carriers.
Conclusions:
Our preliminary data suggest intrinsic differences in the neural differentiation capacity between cell lines
derived from APOE4 or APOE3 carrier subjects. Further experiments would contribute to elucidate novel
pathogenic pathways associated with neurodegeneration and susceptible of therapeutic modulation, likely
contributing to the development of new effective drugs against AD.This study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, co-financed by FEDER funds from
European Union, through grants PI21/00915 (to AG) and PI21/00914 (to JV); by Junta de Andalucia through
Consejería de Economía y Conocimiento grants UMA20-FEDERJA-048 (to JAGL), PY18-RT-2233 (to AG) and
US-1262734 (to JV) co-financed by Programa Operativo FEDER 2014-2020, and Programa Operativo de
Empleo Juvenil SNGJ4-11 to LCP.
Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Co-cultures between neurons and astrocytes to address Alzheimer´s disease pathology.
Background: Alzheimer's disease (AD) is characterized by presenting a complex pathology, not fully resolved yet.
This fact, together with the lack of reliable models, has impeded the development of effective therapies. Recently,
several studies have shown that functional glial cell defects have a key role in the pathology of AD. However, this
glial dysfunction, currently, cannot be correctly modeled using the available animal models, so we hypothesized
that cells derived from Alzheimer's patients can serve as a better platform for studying the disease. In this sense,
human pluripotent stem cells (hPSC) allow the generation of different types of neural cells, which can be used for
disease modeling, identification of new targets and drugs development. Methods: We have a collection of hiPSCs
derived from patients with sporadic forms of AD stratified based on APOE genotype. We have differentiated these
cells towards neural cells and mature them to neurons or astrocytes using a serum-free approach, to assess
intrinsic differences between those derived from AD patients or healthy controls. Results: We have implemented a
serum-free approach and generated neural precursors and astrocytes from all the lines tested. We observe
differences at the phenotypic level and a reduced capacity to differentiate towards neural lineage in those lines
derived from APOE4 carriers. Conclusions: Our preliminary data suggest intrinsic differences in the neural
differentiation capacity between cell lines derived from APOE4 or APOE3 carrier subjects. Further experiments
would contribute to elucidate novel pathogenic pathways associated with neurodegeneration and susceptible of
therapeutic modulation, likely contributing to the development of new effective drugs against AD.This study was
supported by ISCiii (Spain), co-financed by FEDER funds, through grants PI21/00915 (AG) and PI21/00914 (JV);
by Junta de Andalucia through Consejería de Economía and Conocimiento grants UMA20-FEDERJA-048 (JAGL),
PY18-RT-2233 (to AG) and US-1262734 (JV), co-financed by Programa Operativo FEDER 2014-2020, and
SNGJ4-11 (LCP).
Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Human pluripotent stem cell-derived astrocytes from alzheimer´s disease patients for disease modeling
Aims: The lack of reliable models of Alzheimer´s disease (AD) has impeded the development of effective therapies. Glial cells have a key role in AD pathology, but this cannot be properly modeled using available animal models, so we hypothesized that cells derived from Alzheimer's patients can serve as a better platform for studying the disease. In this sense, human pluripotent stem cells (hPSC) allow the generation of different types of neural cells, which can be used for disease modeling, identification of new targets and drugs development. Methods: We have a collection of hiPSCs derived from patients with sporadic forms of AD stratified based on APOE genotype. We have differentiated these cells towards neural lineage to obtain astrocytes to assess intrinsic differences between those derived from AD patients or healthy controls. Results: We have implemented a serum-free approach and generated neural precursors and astrocytes from all the lines tested. Cells are different at the phenotypic level, suggesting intrinsic differences in neural cells derived from AD patients. Conclusions: Human pluripotent stem cell-derived methodology can be used to elucidate the pathogenic pathways associated with neurodegeneration and to identify new therapeutic targets susceptible to modulation, contributing to the development of new effective drugs against AD.Supported by Instituto de Salud Carlos III of Spain PI18/01557, PI21/00915 (to AG), PI18/01556 (to JV), and CIBERNED (CB06/05/1116 to AG and CB06/05/0094 to JV); by Junta de Andalucia UMA18-FEDERJA-211 (to AG), PY18-RT-2233 (to AG) and US-1262734 (to JV), Consejeria de Salud PI-0276-2018 (to JAGL) and Programa Operativo de Empleo Juvenil SNGJ4-11 to LCP. Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Suitability of human-derived cells as a platform for Alzheimer's disease modeling
Aims: Alzheimer's disease (AD) is characterized by presenting a complex pathology, not fully resolved yet. This fact, together with the lack of reliable models, has impeded the development of effective therapies. Recently, several studies have shown that functional glial cell defects have a key role in the pathology of AD. However, this glial dysfunction, currently, cannot be correctly modeled using the available animal models, so we hypothesized that cells derived from Alzheimer's patients can serve as a better platform for studying the disease. In this sense, human pluripotent stem cells (hPSC) allow the generation of different types of neural cells, which can be used for disease modeling, identification of new targets and drugs development. Methods: We have a collection of hiPSCs derived from patients with sporadic forms of AD. We have differentiated these cells towards neural lineage to obtain neurons and astrocytes. For the generation of oligodendrocytes (OLs), we have developed a fast and robust protocol to generate mature OLs in just 22 days. Results: We have generated neural precursors from all the lines tested. In the case of OLs, the cells generated resemble primary OLs and can myelinate neurons in vivo and in vitro using a screening compatible platform. This platform is being transferred for the generation of the other glial cells. Conclusions: This methodology can be used to elucidate the pathogenic pathways associated with neurodegeneration and to identify new therapeutic targets susceptible to modulation, contributing to the development of new effective drugs against AD.This study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, co-financed by FEDER funds from European Union, through grants PI18/01557 (to AG), PI18/01556 (to JV), and CIBERNED (CB06/05/1116 to AG and CB06/05/0094 to JV); by Junta de Andalucia through Consejería de Economía y Conocimiento grants UMA18-FEDERJA-211 (to AG), PY18-RT-2233 (to AG) and US-1262734 (to JV) co-financed by Programa Operativo FEDER 2014-2020 and Consejeria de Salud grant PI-0276-2018 (to JAGL).
Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Alzheimer’s disease (AD) constitutes the most prominent form of dementia among elderly individuals worldwide. Disease modeling using murine transgenic mice was first initiated thanks to the discovery of heritable mutations in amyloid precursor protein (APP) and presenilins (PS) genes. However, due to the repeated failure of translational applications from animal models to human patients, along with the recent advances in genetic susceptibility and our current understanding on disease biology, these models have evolved over time in an attempt to better reproduce the complexity of this devastating disease and improve their applicability. In this review, we provide a comprehensive overview about the major pathological elements of human AD (plaques, tauopathy, synaptic damage, neuronal death, neuroinflammation and glial dysfunction), discussing the knowledge that available mouse models have provided about the mechanisms underlying human disease. Moreover, we highlight the pros and cons of current models, and the revolution offered by the concomitant use of transgenic mice and omics technologies that may lead to a more rapid improvement of the present modeling batterThis research was funded by INSTITUTO DE SALUD CARLOS III (ISCiii) of Spain, cofinanced by FEDER funds from European Union, through grants PI21/00915 (to AG) and PI21/00914 (to JV); by JUNTA DE ANDALUCIA CONSEJERÍA DE ECONOMÍA Y CONOCIMIENTO through grants UMA18-FEDERJA-211 (to AG), UMA20-FEDERJA-104 (to IMG), P18-RT-2233 (to AG) and US-1262734 (to JV) co-financed by Programa Operativo FEDER 2014–2020 and CONSEJERIA DE SALUD grant PI-0276-2018 (to JAGL); by SPANISH MINISTER OF SCIENCE AND INNOVATION grant PID2019-108911RA-100 (to DBV), BEATRIZ GALINDO PROGRAM BAGAL18/00052 (to DBV), Alzheimer Association AARG-22-928219 (to DBV), grant PID2019-107090RA-100 (to IMG) and RAMON Y CAJAL PROGRAM RYC-2017-21879 (to IMG); and by MALAGA UNIVERSITY grant B1-2019_07 (to ESM), grant B1-2020_04 (to JAGL), grant B1-2019_06 (to IMG) and NASARD grant 27565 2018 (to IMG). M.M.-O. held a predoctoral contract from Malaga University, J.J.F.-V. held a postdoctoral contract from Malaga University, and E.S.-M. a postdoctoral contract (DOC_00251) from Junta de Andalucia. Partial funding for open access charge: Universidad de Málaga
Generation and characterization of human ipscderived neural precursors and astrocytes to model Alzeimer’s disease
Background: Alzheimer's disease (AD) is characterized by presenting a
complex pathology, not fully resolved yet. This fact, together with the lack
of reliable models, has impeded the development of effective therapies.
Recently, several studies have shown that functional glial cell defects have
a key role in the pathology of AD. However, this glial dysfunction,
currently, cannot be correctly modeled using the available animal models,
so we hypothesized that cells derived from Alzheimer's patients can serve as
a better platform for studying the disease. In this sense, human pluripotent
stem cells (hPSC) allow the generation of different types of neural cells,
which can be used for disease modeling, identification of new targets and
drugs development.
Methods: We have a collection of hiPSCs derived from patients with
sporadic forms of AD stratified based on APOE genotype. We have
differentiated these cells towards neural cells and mature them to neurons or
astrocytes using a serum-free approach, to assess intrinsic differences
between those derived from AD patients or healthy controls.
Results: We have implemented a serum-free approach and generated
neural precursors and astrocytes from all the lines tested. We observe
differences at the phenotypic level and a reduced capacity to differentiate
towards neural lineage in those lines derived from APOE4 carriers.
Conclusions: Our preliminary data suggest intrinsic differences in the
neural differentiation capacity between cell lines derived from APOE4 or
APOE3 carrier subjects. Further experiments would contribute to elucidate
novel pathogenic pathways associated with neurodegeneration and
susceptible of therapeutic modulation, likely contributing to the
development of new effective drugs against AD.Acknowledgments:
This study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, cofinanced
by FEDER funds from European Union, through grants PI21/00915 (to
AG) and PI21/00914 (to JV); by Junta de Andalucia through Consejería de
Economía y Conocimiento grants PY18-RT-2233 (to AG) and US-1262734 (to JV)
co-financed by Programa Operativo FEDER 2014-2020, Consejeria de Salud grant
PI-0276-2018 (to JAGL) and Programa Operativo de Empleo Juvenil SNGJ4-11 to
LCP.
Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Human pluripotent stem cells as a research tool for elucidating the role of glial cells in Alzheimer´s disease
Background:
Alzheimer's disease (AD) is characterized by presenting a complex pathology,
not fully resolved yet. This fact, together with the lack of reliable models, has
impeded the development of effective therapies. Recently, several studies have
shown that functional glial cell defects have a key role in the pathology of AD.
However, this glial dysfunction, currently, cannot be correctly modeled using
the available animal models, so we hypothesized that cells derived from
Alzheimer's patients can serve as a better platform for studying the disease. In
this sense, human pluripotent stem cells (hPSC) allow the generation of
different types of neural cells, which can be used for disease modeling,
identification of new targets and drugs development.
Methods:
We have a collection of hiPSCs derived from patients with sporadic forms of
AD. We have differentiated these cells towards neural lineage to obtain neurons
and astrocytes. For the generation of oligodendrocytes (OLs), we have
developed a fast and robust protocol to generate mature OLs in just 22 days.
Results:
We have generated neural precursors from all the lines tested. In the case of
OLs, the cells generated resemble primary OLs and can myelinate neurons in
vivo and in vitro using a screening compatible platform. This platform is being
transferred for the generation of the other glial cells.
Conclusions:
This methodology can be used to elucidate the pathogenic pathways associated
with neurodegeneration and to identify new therapeutic targets susceptible to
modulation, contributing to the development of new effective drugs against AD.Acknowledgments:
J.A.G.L has been supported by a contract of doctor reincorporation plan from
the I Plan Propio of the University of Malaga (Spain) and by CIBERNED. This
study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, cofinanced
by FEDER funds from European Union, through grants PI18/01557 (to
AG), PI18/01556 (to JV), and CIBERNED (CB06/05/1116 to AG and
CB06/05/0094 to JV); by Junta de Andalucia through Consejería de Economía y
Conocimiento grants UMA18-FEDERJA-211 (to AG), PY18-RT-2233 (to AG)
and US-1262734 (to JV) co-financed by Programa Operativo FEDER 2014-
2020 and Consejeria de Salud grant PI-0276-2018 (to JAGL).Acknowledgments:
J.A.G.L has been supported by a contract of doctor reincorporation plan from
the I Plan Propio of the University of Malaga (Spain) and by CIBERNED. This
study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, cofinanced
by FEDER funds from European Union, through grants PI18/01557 (to
AG), PI18/01556 (to JV), and CIBERNED (CB06/05/1116 to AG and
CB06/05/0094 to JV); by Junta de Andalucia through Consejería de Economía y
Conocimiento grants UMA18-FEDERJA-211 (to AG), PY18-RT-2233 (to AG)
and US-1262734 (to JV) co-financed by Programa Operativo FEDER 2014-
2020 and Consejeria de Salud grant PI-0276-2018 (to JAGL).
Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Fast and efficient generation of oligodendrocytes from human induced pluripotent stem cells (hiPSCs)
Acknowledgments:
This study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, co-financed by FEDER funds from European Union, through grants PI18/01557 (to AG), PI18/01556 (to JV), and CIBERNED (CB06/05/1116 to AG and CB06/05/0094 to JV); by Junta de Andalucia through Consejería de Economía y Conocimiento grants UMA18-FEDERJA-211 (to AG), PY18-RT-2233 (to AG) and US-1262734 (to JV) co-financed by Programa Operativo FEDER 2014-2020 and Consejeria de Salud grant PI-0276-2018 (to JAGL).Oligodendrocytes (OLs) are highly specialized cells of the central nervous system responsible for myelin production and metabolic support of neurons. Defects in OLs are crucial in several neurodegenerative diseases including multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Scarce access to primary samples and lack of efficient protocols to generate OLs from human pluripotent stem cells (hPSCs) are hampering our understanding of OL biology and the development of novel therapies.
To promote the conversion of hPSCs into OLs, we have screened for a number of transcription factors (TFs) previously reported to be involved in OL generation. We found that the overexpression of SOX10 was sufficient to generate O4+ oligodendrocyte precursor cells (OPCs) from hPSCs only 10 days after SOX10 induction. Generated OPCs expressed mature OL proteins as MBP or MOG. At the transcriptome level, generated OPCs resembled primary OPCs. To test the functionality of generated OPCs, O4+ cells were co-cultured together with neurons, finding that O4+ cells were able to myelinate the neurons. Moreover, O4+ cells were injected intracerebrally in newborn shiverer RAG2-/- mice, finding that generated OLs extended within the corpus callosum and generated functional myelin, demonstrating the functionality of generated cells also in vivo. The protocol also describes an alternative for viral transduction, by incorporating an inducible SOX10 in the safe harbor locus AAVS1, yielding ~100% pure OPCs. O4+ OPCs can be co-cultured with maturing hPSC-derived neurons in 96/384-well- format plates, allowing the screening of pro-myelinating compounds.
We have developed a novel methodology for a fast (20 days from hPSC stage) and efficient generation of functional OLs, which allow testing of compounds involved in myelination. This technology will allow further studies to better understand human OL biology and the screening of potential compounds involved in myelination in a human setting.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech